{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:22:21Z","timestamp":1767687741485,"version":"3.48.0"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100016022","name":"Data Center of Management Science, National Natural Science Foundation of China - Peking University","doi-asserted-by":"publisher","award":["No.U20A20346"],"award-info":[{"award-number":["No.U20A20346"]}],"id":[{"id":"10.13039\/501100016022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite the established efficacy of ustekinumab (UST) in Crohn\u2019s disease (CD), real-world studies reveal suboptimal treatment persistence and limited endoscopic healing. Current optimization paradigms remain constrained by suboptimal durability and escalating therapeutic demands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the clinical utility and safety of intravenous (IV) ustekinumab maintenance therapy in CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a single-center retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This study included CD patients receiving \u2a7e2 IV-UST maintenance infusions between June 2020 and October 2023 (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u2009234). The protocol featured weight-based induction-equivalent dosing (260\u2013520\u2009mg) at response-guided intervals. The primary endpoint was the corticosteroid-free clinical remission rate at Week 24.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At 24\u2009weeks, 88.1% (185\/210) achieved steroid-free remission with C-reactive protein (CRP) normalization in 90.0% (44\/88). Median Harvey-Bradshaw Index decreased from 4 (interquartile range (IQR) 2\u20135) to 2 (IQR 1\u20133;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). 52-week endoscopic remission (simplified endoscopic score for Crohn\u2019s disease \u2a7d3) reached 48.7% (56\/115), with fecal calprotectin normalization in 33.6% (35\/104). Multivariate analysis identified baseline CRP &gt;5\u2009mg\/L (adjusted odds ratio (aOR) 3.62, 1.16\u201311.25), intensive dosing (\u2a7e6\u2009cycles\/year; aOR 12.06, 1.99\u201373.05), and disease duration \u2a7e1\u2009year (aOR 3.53, 1.08\u201311.54) as predictors of endoscopic non-remission. Safety analysis demonstrated 44.4% adverse event incidence (104\/234) and 3.0% serious adverse events (7\/234).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IV-UST maintenance demonstrates high rates of corticosteroid-free clinical remission and endoscopic healing with manageable safety in CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848251375356","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:46:08Z","timestamp":1759725968000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous ustekinumab maintenance in Crohn\u2019s disease: a single-center retrospective cohort study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0169-2611","authenticated-orcid":false,"given":"Yuting","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"},{"name":"Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-2560","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University No. 88 Jiefang Road, Hangzhou 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz119"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001074"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14487"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab081"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-06932-4"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(21)01043-X"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad184"},{"issue":"10","key":"e_1_3_4_10_2","first-page":"1453","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"45","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007; 45(10): 1453\u20131457.","journal-title":"Prev Med"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.128"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"issue":"2","key":"e_1_3_4_14_2","first-page":"71","article-title":"Development and validation of the assessment for effective intervention","volume":"36","author":"Cook CR","year":"2011","unstructured":"Cook CR, Rasetshwane KB, Truelson E, et al. Development and validation of the assessment for effective intervention. Assess Eff Interv 2011; 36(2): 71\u201379.","journal-title":"Assess Eff Interv"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.10.002"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab357"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251375356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251375356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251375356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:18:03Z","timestamp":1767687483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251375356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":15,"alternative-id":["10.1177\/17562848251375356"],"URL":"https:\/\/doi.org\/10.1177\/17562848251375356","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"17562848251375356"}}